Granulocyte Transfusions — NCD 144 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 144, the national coverage determination governing granulocyte transfusions, effective March 7, 2026. Here's what billing teams need to know.

CMS granulocyte transfusion coverage policy under NCD 144 in the CMS Medicare system covers transfusions for patients with severe infection and granulocytopenia — but only under two specific clinical scenarios. This policy applies across inpatient hospital, outpatient hospital, and physician service benefit categories. No specific CPT or HCPCS codes are listed in the policy document itself, which creates a documentation burden your billing team needs to manage carefully.

Quick-Reference Table

CMS Granulocyte Transfusion Coverage Criteria and Medical Necessity Requirements 2026

NCD 144 is the National Coverage Determination governing Medicare coverage of granulocyte transfusions. The Centers for Medicare & Medicaid Services covers granulocyte transfusions when a patient has both severe infection and granulocytopenia. That combination is the floor — not either condition alone.

CMS defines granulocytopenia as fewer than 500 granulocytes/mm³ of whole blood. Your documentation needs to show this threshold is met. A lab result confirming sub-500 granulocyte count is not optional — it's the medical necessity anchor for any claim under this coverage policy.

From there, the CMS granulocyte transfusion coverage policy narrows to two accepted indications:

Indication 1: Granulocytopenia with evidence of gram negative sepsis.

Indication 2: Granulocytopenia in febrile patients with local progressive infections unresponsive to appropriate antibiotic therapy, thought to be due to gram negative organisms.

Both indications require granulocytopenia as a baseline. Neither applies without it.

The second indication adds more documentation weight. You need to show the infection is local and progressive, that appropriate antibiotic therapy was tried and failed, and that gram negative organisms are the suspected cause. "Thought to be due to gram negative organisms" is a clinical judgment call — but your billing team needs that judgment in writing, in the chart, before the claim goes out.

This is where claim denial risk concentrates. Vague documentation like "infection not responding to antibiotics" won't hold up. The record needs to connect the dots: granulocyte count below 500, antibiotic trial, documented failure, gram negative suspicion. Every link in that chain needs to be in the notes.

The policy does not mention prior authorization requirements for granulocyte transfusions under NCD 144. That doesn't mean your Medicare Administrative Contractor won't have additional requirements at the local level. Check with your MAC before assuming prior authorization isn't needed — local coverage determinations can layer on top of national ones.

The benefit categories here are broad: inpatient hospital services, outpatient hospital services incident to a physician's service, and physicians' services. That means NCD 144 applies across your inpatient and outpatient settings. If your system bills granulocyte transfusions in both settings, both need the same documentation discipline.

Coverage Indications at a Glance

CMS Granulocyte Transfusion Billing Guidelines and Action Items 2026

The effective date of March 7, 2026 is already here. If your team bills granulocyte transfusions for Medicare patients, these are the steps to take now.

The real risk here isn't complexity — this is a relatively narrow policy. The risk is assuming the clinical record is good enough without checking. Granulocyte transfusion billing lives or dies on documentation specificity.

CPT, HCPCS, and ICD-10 Codes for Granulocyte Transfusions Under NCD 144

A Note on Code Availability

NCD 144 does not list specific CPT, HCPCS, or ICD-10 codes in the policy document. This is not uncommon for older national coverage determinations — the code sets evolve, and the NCD itself doesn't always track with them.

This puts the burden on your billing team to confirm the correct codes with your Medicare Administrative Contractor. Do not rely on internal assumptions or legacy code mappings without current MAC confirmation.

What to Ask Your MAC

When you contact your MAC, ask specifically:

• What procedure codes does your MAC accept for granulocyte transfusion claims billed under NCD 144?
• Are there revenue codes required for inpatient or outpatient hospital billing of granulocyte transfusions?
• What ICD-10-CM diagnosis codes does your MAC expect to see on claims for NCD 144 indications — specifically gram negative sepsis and gram negative organism infections?
• Are there any local coverage determinations at your MAC that layer on top of NCD 144?

Getting these answers in writing from your MAC protects your reimbursement and gives you a defensible billing record if claims are audited.

Diagnosis Code Guidance (Confirm with MAC)

While NCD 144 does not specify ICD-10-CM codes, the two covered indications point to well-defined clinical scenarios. Gram negative sepsis and progressive gram negative infections are mapped in ICD-10-CM. Your clinical documentation team should be coding to the highest specificity available — including organism-level specificity where the record supports it.

Work with your coding staff and MAC to align diagnosis coding to the clinical criteria in NCD 144. Coding "sepsis" without organism specificity when the record supports gram negative sepsis is a missed opportunity for documentation alignment — and a potential medical necessity flag.